Navigation Links
Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab

Sphingomab Shows Near-Complete Mitigation of Choroidal Neovascularization (CNV) in an AMD Model

SAN DIEGO, May 22, 2007 /PRNewswire-FirstCall/ -- Lpath, Inc. , the category leader in therapeutic agents against bioactive lipids, reported compelling proof-of-concept data in a standard animal model of human age-related macular degeneration (AMD).

The results were presented at the annual meeting of the Association of Research in Vision and Ophthalmology (ARVO) by Glenn L. Stoller, M.D., head of Lpath's ocular therapies division. Stoller reported that Lpath's lead drug candidate Sphingomab (in its humanized form) mitigated almost completely the choroidal neovascularization (CNV) formation in mice with laser-induced choroidal damage, which mimics the pathologic neovascularization experienced by patients with AMD.

Sphingomab, generated by Lpath's proprietary ImmuneY2(TM) platform technology, is a monoclonal antibody against the bioactive lipid S1P (sphingosine-1-phosphate). S1P has been well validated as a stimulator of angiogenesis (new blood-vessel growth), a process that has been strongly implicated in the progression of both AMD and cancer.

Moreover, S1P has recently garnered considerable attention in the scientific community as a validated mediator of fibrosis (scar-tissue formation), which contributes significantly to AMD-related vision loss. Lpath has demonstrated in previous studies that Sphingomab reduces scarring in a variety of organ systems by inhibiting S1P.

"This is the first demonstration that S1P is a mediator of CNV in an AMD model," said Stoller, "and that antibody-mediated inhibition of S1P is highly effective in preventing abnormal-blood-vessel growth beneath the retina."

Scott Pancoast, Lpath's president and CEO, added, "This near-complete mitigation of CNV establishes compelling pre-clinical efficacy for Sphingomab. Inhibition of S1P is a novel approach to treat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
9. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
10. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
11. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Post Your Comments:
(Date:11/25/2009)...v.25/PRNewswire/--BioTrendsResearchGroup,Inc.relea...t,thefirstinamulti-phasesyndicatedmarketresearchpr...lara,fromproductlaunchthroughthefirstsixmonthsofav...informationfrom75uniqueDermatologistsandqualitativ...nduseofStelara,obstaclestouse,typicalpatienttypes,...
(Date:11/25/2009)...Md.,Nov.25/PRNewswire-USNewswire/--RemediumTechnol...thatstopsseverebleeding,wonfirstprizeand$10,000int...rityChallenge2009,companyofficialsannouncetoday. ,...rld,Remedium,steampitchedtheirinventionattheGSCSec...ss. ,, Remedium( www.remediumtechnologies.com )...
(Date:11/25/2009)...,Nov.25/PRNewswire-Asia-FirstCall/--ChinaSkyOne,Me...daq: CSKI ),a,leadingfullyintegratedpharmaceutical...sinthePeople,sRepublicofChina("PRC"),today,announc...stitutefor,theControlofPharmaceuticalandBiological...s:itsDiagnosticKitforHumanProstateSpecific,Antigen...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3REPEAT 3A Project Runway Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positiv 57712 1REPEAT 3A Project Runway Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positiv 57712 2REPEAT 3A Project Runway Designer in New Orleans to Educate About Living with HIV and Combat Stigma Associated with the Disease through Living Positiv 57712 3U S Census Bureau Daily Feature for Sept 20 57708 1Strain on nanocrystals could yield colossal results 14156 1Strain on nanocrystals could yield colossal results 14156 2Strain on nanocrystals could yield colossal results 14156 3
...lls Inc. (BCI), a,biopharmaceutical company utiliz...p compounds that promote the growth of new neurons... diseases, announced today that it has,initiated a...didate,BCI-540, for the treatment of depression wi... expressed by our clinical,investigators who view ...
...Predictable, Extended Exposure with Sustained- ...O, April 17 Data from the first pivotal study of,...ional compound to treat,Restless Legs Syndrome (RL...toms of moderate-to-severe primary RLS compared to...ministered once-daily for 12 weeks., Data from th...
Other Medicine Technology:BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety 2Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 2Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 3Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 4Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 5Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 6
(Date:11/27/2009)....Y.,Nov.27/PRNewswire-USNewswire/--Preventingdisea...everyyear,newvaccinesarebeingaddedtoassistindiseas...eperiodoftime?And,ifnot,whenareadditional,boosters...,sissueofPediatrics,theJournaloftheAmericanAcademy...esterGeneralResearchInstitute,basedatRochesterGene...
(Date:11/27/2009)... XenaCare Holdings has announced that it has...tion, one of the largest nonprofit organizations d...ducation. , Delray Beach,..., Inc. (OTCBB: XCHO), a company specializing in th...althcare products, has announced today that is has...
(Date:11/27/2009)....27/PRNewswire/-- Allrecipes.com , theworld,s#1fo...rs,withmorethan2.8millionvisitorsthedaybeforeThank...biggestfoodholidayoftheyear.TheaverageThanksgiving...centincreasefromlastyear,sfeast.AccordingtotheAllr...opularThanksgivingrecipe,acontrastfromlastyear,spo...
(Date:11/27/2009)... Specialist manufacturers who use medical lo... millions of dollars by bringing in technology par...ng numbers of pro-active medical manufacturers are...pt stage of their projects, ensuring that progress...ses or potentially outdated technology. , ...
(Date:11/26/2009)....J.,Nov.27/PRNewswire/--Thediabetespopulationinthe...nnualmedicalspendingonthediseaseisprojectedtohit$3...publishedintheDecemberissueof DiabetesCare .TheNat...mofNovoNordisk,commissionedtheanalysisbyateamfromt...t,thenumberofAmericanslivingwithdiabeteswillrisefr...
Breaking Medicine News(10 mins):Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3
...e Senior Living Inc. (NYSE: BKD ) announced toda...to a Second Amended and Restated Credit Agreement....million revolving loan facility and matures in Aug... the aggregate. The letter of credit facilities m...
...in Shapiro, PhD, have collaborated for 20 years to...center at Barrow Neurological Institute at St. Jos...dedicated patient care and research, the Shapiros ... allow Barrow to hire the best and the brightest t...
... MD Salon & Hair Replacement Center, Hair Fant...cement services for clients battling with hair los... Greenbelt, MD (PRWEB) February 27, 2009 -- ...amage, side effects from medication, iron or zinc ...
...utes to a Healthier, More Productive Practice , ,...ented integration of technology and is well-positi... The new A-dec 300 system offers customers a mid-l...cts. , , (Photo: http://www.newscom.com/cgi-bi...
...n of Wound Care and Ophthalmics Business of Unomed...ble Healthcare Partners ("RoundTable"), an operati...y on the healthcare industry, announced today that...cal Limited ("Unomedical") based in Redditch, U.K....
... global clinical research organization announced t...post of Director, Late Phase, Europe. , , Ms. T...w position in Chiltern,s global Late Phase Organiz...operational side of management in both industries....
Other Medicine News:Health News:Brookdale Amends and Extends Corporate Line of Credit 2Health News:Brookdale Amends and Extends Corporate Line of Credit 3Health News:A lifetime of paying it forward 2Health News:Inspired Cancer Survivor Launches Customized Hair Replacement ,Techniques at Award-Winning Hair Salon 2Health News:New A-dec 300(TM) Offers Dentists an Innovative Equipment Solution 2Health News:RoundTable Healthcare Partners Leads Portfolio Company Add-On Acquisition 2Health News:RoundTable Healthcare Partners Leads Portfolio Company Add-On Acquisition 3Health News:Chiltern Appoints Jane Turner as Late Phase Director for Europe 2
ABX Micros IM Hematology Analyzers
Sequitor™ Steerable Guidewire
Rio™ Aspiration Catheter
Reference Lab Interface (RLI)©
Medicine Products: